Watchlist Price Alert

Vertex Pharmaceuticals (VRTX)

NASDAQ: VRTX · Real-Time Price · USD

454.22

2.06 (0.46%)

At close: Jul 02, 2025, 10:36 AM

0.46% (1D)

Bid	454.5
Market Cap	116.64B
Revenue (ttm)	11.1B
Net Income (ttm)	-988.9M
EPS (ttm)	-3.84
PE Ratio (ttm)	-118.29
Forward PE	21.43
Analyst	Buy

Ask	455.04
Volume	162,710
Avg. Volume (20D)	1,732,288
Open	449.81
Previous Close	452.16
Day's Range	448.00 - 456.12
52-Week Range	377.85 - 519.88
Beta	0.42

About VRTX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol VRTX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for VRTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Vertex Pharmaceuticals is scheduled to release its earnings on Jul 31, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-10.03%

Vertex Pharmaceuticals shares are trading lower af... Unlock content with Pro Subscription

1 month ago

-0.19%

Vertex Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 financial results.

News

Just now · zacks.com

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Just now · zacks.com

Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.

21 hours ago · zacks.com

Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts

Vertex Pharmaceuticals (VRTX) reached $452.16 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close.

20 hours ago · reuters.com

Vertex's next-generation cystic fibrosis drug gets EU approval

Vertex said on Tuesday that its next-generation drug, Alyftrek, gained European Commission approval for the treatment of cystic fibrosis.

21 hours ago · businesswire.com

Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment ...

1 week ago · businesswire.com

Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea

BOSTON & OSAKA, Japan--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agre...

1 week ago · seekingalpha.com

Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Diabetes Association (ADA) 85th Scientific Sessions Conference Transcript

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) American Diabetes Association (ADA) 85th Scientific Sessions Conference June 20, 2025 8:15 PM ET Company Participants James Markmann - Corporate Part...

1 week ago · businesswire.com

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORW...